Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Wang, Jian ^a   Svendsen, Agnete ^a   Kmiecik, Justyna ^a   Immervol, Heike ^a,b   Skaftnesmo, Kai Ove ^a   Planagumà, Jesús ^a   Reed, Rolf Kåre ^b   Bjerkvig, Rolf ^a,c   Miletic, Hrvoje ^a,b   Enger, Per Øyvind ^a,b   Rygh, Cecilie Brekke ^a,b   Chekenya, Martha ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; NEURON GLIA 2; PROTEOGLYCAN; RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTIGEN; CHONDROITIN SULFATE PROTEOGLYCAN 4; SMALL INTERFERING RNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DISEASE COURSE; GLIA; GLIOBLASTOMA; GROWTH RATE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN FUNCTION; PROTEIN TARGETING; XENOGRAFT; ANIMAL; BRAIN TUMOR; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); NONOBESE DIABETIC MOUSE; NUDE RAT; PATHOLOGY; PHYSIOLOGY; RAT; TRANSGENE;

ANIMALIA;

ANIMALS; ANTIGENS; BRAIN NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; RATS; RATS, NUDE; RNA, SMALL INTERFERING; TRANSGENES;

EID: 79960930688     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023062     Document Type: Article

References (39)

1. Ohgaki H, Kleihues P, (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: 479-489.
2. Smith JS, Jenkins RB, (2000) Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 5: D213-231.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
4. Behm FG, Smith FO, Raimondi SC, Pui CH, Bernstein ID, (1996) Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 87: 1134-1139.
5. Chekenya M, Enger PO, Thorsen F, Tysnes BB, Al-Sarraj S, et al. (2002) The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol 28: 367-380.
6. Mauvieux L, Delabesse E, Bourquelot P, Radford-Weiss I, Bennaceur A, et al. (1999) NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases. Br J Haematol 107: 674-676.
7. Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA, et al. (1991) Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51: 4986-4993.
8. Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, et al. (1999) Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci U S A 96: 10361-10366.
9. Smith FO, Rauch C, Williams DE, March CJ, Arthur D, et al. (1996) The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 87: 1123-1133.
10. Chekenya M, Hjelstuen M, Enger PO, Thorsen F, Jacob AL, et al. (2002) NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. Faseb J 16: 586-588.
11. Goretzki L, Lombardo CR, Stallcup WB, (2000) Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen). J Biol Chem 275: 28625-28633.
12. Chekenya M, Krakstad C, Svendsen A, Netland IA, Staalesen V, et al. (2008) The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene 27: 5182-5194.
13. Li Y, Madigan MC, Lai K, Conway RM, Billson FA, et al. (2003) Human uveal melanoma expresses NG2 immunoreactivity. Br J Ophthalmol 87: 629-632.
14. Benassi MS, Pazzaglia L, Chiechi A, Alberghini M, Conti A, et al. (2008) NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J Orthop Res doi:10.1002/jor.20694.
15. Burg MA, Grako KA, Stallcup WB, (1998) Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J Cell Physiol 177: 299-312.
16. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, et al. (2001) Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 19: 29-34.
17. Rainov NG, (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389-2401.
18. Folkman J, (2003) Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2: S127-133.
19. Peroulis I, Jonas N, Saleh M, (2002) Antiangiogenic activity of endostatin inhibits C6 glioma growth. Int J Cancer 97: 839-845.
20. Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O, (1999) Growth of precultured human glioma specimens in nude rat brain. J Neurosurg 90: 125-132.
21. Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, et al. (2003) Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol 105: 49-57.
22. Wang J, Miletic H, Sakariassen PO, Huszthy PC, Jacobsen H, et al. (2009) A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 9: 465.
23. Festing MF, May D, Connors TA, Lovell D, Sparrow S, (1978) An athymic nude mutation in the rat. Nature 274: 365-366.
24. Brekke C, Lundervold A, Enger PO, Brekken C, Stalsett E, et al. (2006) NG2 expression regulates vascular morphology and function in human brain tumours. Neuroimage 29: 965-976.
25. Su MY, Jao JC, Nalcioglu O, (1994) Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. Magn Reson Med 32: 714-724.
26. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223-232.
27. Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, et al. (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92: 1599-1610.
28. Schoenegger K, Oberndorfer S, Wuschitz B, Struhal W, Hainfellner J, et al. (2009) Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma? Eur J Neurol 16: 874-878.
29. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972.
30. Keunen OJ, Oudin M, Sanzey A, Abdul-Rahim M, Fack SA, et al. (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. PNAS 108: 3749-3754.
31. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, et al. (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61: 6624-6628.
32. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, et al. (2008) Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. Int J Radiat Oncol Biol Phys 71: 1372-1380.
33. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
34. Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, et al. (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 11: 4934-4940.
35. Lund-Johansen M, Bjerkvig R, Humphrey PA, Bigner SH, Bigner DD, et al. (1990) Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 50: 6039-6044.
36. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, et al. (2010) Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12: 466-472.
37. Hovinga KE, Stalpers LJ, van Bree C, Donker M, Verhoeff JJ, et al. (2005) Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines--a clue to radioresistance? J Neurooncol 74: 99-103.
38. Hjortland GO, Garman-Vik SS, Juell S, Olsen OE, Hirschberg H, et al. (2004) Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg 100: 320-327.
39. Kutner RH, Zhang XY, Reiser J, (2009) Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 4: 495-505.